Drug Profile
Phaleria macrocarpa extract
Alternative Names: DLBS 1425; PhalecarpsLatest Information Update: 07 Oct 2015
Price :
$50
*
At a glance
- Originator Dexa Medica
- Class Antineoplastics; Phytotherapies
- Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; Apoptosis stimulants; Caspase stimulants; Proto oncogene protein c-akt inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Marketed Breast cancer
Most Recent Events
- 30 Nov 2012 Dexa Medica Group completes a phase II/III trial in Breast cancer (neoadjuvant therapy) in Indonesia (NCT01433562)
- 10 Oct 2012 Dexa Medica Group terminates a phase II trial for Breast cancer in Indonesia (NCT01006785)
- 08 Apr 2012 Dexa Medica Group initiates enrolment in a phase II trial for Breast cancer in Indonesia (NCT01006785)